ライフサイエンスコーパス: rhabdomyolysis

1 es (delayed nephrotoxic, delayed neurotoxic, rhabdomyolysis).

2 and common compounds that cause drug-induced rhabdomyolysis.

3 lt in an excellent prognosis of drug-induced rhabdomyolysis.

4 otherapy substantially increased the risk of rhabdomyolysis.

5 mon pediatric drugs that are associated with rhabdomyolysis.

6 istration (FDA) reports on statin-associated rhabdomyolysis.

7 decrease renal injury after glycerol-induced rhabdomyolysis.

8 with symptoms of recurrent exercise-induced rhabdomyolysis.

9 rate climates with increasing frequency, and rhabdomyolysis.

10 issue levels and predisposing the patient to rhabdomyolysis.

11 th a significantly higher risk of exertional rhabdomyolysis.

12 null mutations in the LPIN1 gene suffer from rhabdomyolysis.

13 without intellectual disability, or isolated rhabdomyolysis.

14 presented with acute polymyositis leading to rhabdomyolysis.

15 n, and the neuroleptic malignant syndrome or rhabdomyolysis.

16 lovastatin contributes to increased risk of rhabdomyolysis.

17 iver enzymes, muscle aches, and very rarely, rhabdomyolysis.

18 effects ranging in severity from myalgias to rhabdomyolysis.

19 number of side effects in muscle, including rhabdomyolysis.

20 known to cause myopathy and, in rare cases, rhabdomyolysis.

21 eful monitoring due to the increased risk of rhabdomyolysis.

22 ted adverse effect with this group of drugs, rhabdomyolysis.

23 each with advanced liver disease, developed rhabdomyolysis.

24 se in malignancy, transaminase elevation, or rhabdomyolysis.

25 x into the growing limb muscle fibers causes rhabdomyolysis.

26 regarding myopathy, which may lead to fatal rhabdomyolysis.

27 liver toxicity, and muscle toxicity without rhabdomyolysis.

28 number needed to treat, and relative risk of rhabdomyolysis.

29 1.9 [1.4-2.6]), hypotension (1.8 [1.3-2.3]), rhabdomyolysis (1.8 [1.3-2.3]), or dyslipidemia (2.0 [1.

30 not stopped, to the more severe condition of rhabdomyolysis), 50-100 new cases of diabetes, and 5-10

31 with a higher risk for hospitalization with rhabdomyolysis (absolute risk increase, 0.02% [95% CI, 0

32 tion and management of both pressure-induced rhabdomyolysis and anastomotic failure after bariatric s

33 injury, and increased levels of apoptosis in rhabdomyolysis and cisplatin-induced AKI, despite signif

34 dels to test whether the risks of exertional rhabdomyolysis and death varied according to sickle cell

35 tely triggers sustained muscle contractions, rhabdomyolysis and death.

36 cell trait elevates the risks of exertional rhabdomyolysis and death.

37 hanges are thought to contribute to fatigue, rhabdomyolysis and disruption of excitation-contraction

38 Results were sensitive to rates of rhabdomyolysis and drug costs.

39 erse events: one (4%) of 25 each had grade 3 rhabdomyolysis and grade 2 hypothyroidism; grade 3 irido

40 describe a patient who presented with acute rhabdomyolysis and had 68% cytochrome c oxidase (COX)-de

41 is a controversial treatment of drug-induced rhabdomyolysis and has proven to be beneficial in some p

42 ported to date and only the second with both rhabdomyolysis and hemolysis.

43 eakness, with death at age 4 associated with rhabdomyolysis and hyperkalemia.

44 oglycemia, (cardio)myopathy, arrhythmia, and rhabdomyolysis and illustrates the importance of FAO dur

45 at risk for ischemia-induced organ failure, rhabdomyolysis and muscle compartment syndromes, and ven

46 ation are a common cause of exercise-induced rhabdomyolysis and myoglobinuria.

47 The risk of rhabdomyolysis and other adverse effects with statin use

48 disease, which is characterized by recurrent rhabdomyolysis and peripheral neuropathy, but without in

49 NA gene point mutation presenting with acute rhabdomyolysis and recurrent myoglobinuria.

50 nically important muscle symptoms, including rhabdomyolysis and statin-induced necrotizing autoimmune

51 for oxidative injury in the renal failure of rhabdomyolysis and suggest that the protective effect of

52 (for more than 2 years in one child), and of rhabdomyolysis and weakness in the others.

53 Muscle injury (rhabdomyolysis) and subsequent deposition of myoglobin i

54 duction and rates of elevated liver enzymes, rhabdomyolysis, and cancer per 100,000 person-years was

55 owering and rates of elevated liver enzymes, rhabdomyolysis, and cancer.

56 in patients with CKD, the increased risk of rhabdomyolysis, and competing risks associated with prog

57 receptor (RyR1) display muscle contractures, rhabdomyolysis, and death in response to elevated enviro

58 y depression, cardiac arrhythmias, seizures, rhabdomyolysis, and hypoglycemia.

59 ent disappearance of chronic cardiomyopathy, rhabdomyolysis, and muscle weakness (for more than 2 yea

60 s, in many cases, to prevent cardiomyopathy, rhabdomyolysis, and muscle weakness.

61 phy, one presented with isolated episodes of rhabdomyolysis, and one as a congenital muscular dystrop

62 ficant elevations in creatinine kinase), and rhabdomyolysis are 190, 5, and 1.6 per 100,000 patient y

63 some statins on muscle, such as myopathy and rhabdomyolysis, are rare at standard doses, and on the l

64 aracterized by encephalopathy, hypoglycemia, rhabdomyolysis, arrhythmias, and laboratory findings sug

65 on with lovastatin did not cause significant rhabdomyolysis as assessed by measuring the levels of cr

66 uly 1999 also suggested an increased risk of rhabdomyolysis associated with high doses of cerivastati

67 -induced oxidative stress, e.g., therapy for rhabdomyolysis-associated renal dysfunction.

68 nexpectedly, inactivity was not explained by rhabdomyolysis, but rather reflected the overall reduced

69 served in rat kidneys after glycerol-induced rhabdomyolysis, but the role of macrophages in rhabdomyo

70 Rhabdomyolysis can be life threatening if complicated by

71 The resulting muscle necrosis (rhabdomyolysis) causes acute renal injury.

72 AKI: ischemia/reperfusion, glycerol-induced rhabdomyolysis, cisplatin nephrotoxicity, and bilateral

73 Rhabdomyolysis during EVD has been suggested to occur in

74 ents, there was development of myositis with rhabdomyolysis, early progressive and refractory cardiac

75 eak syndrome (VLS), aphasia, and evidence of rhabdomyolysis encountered at 24 mg/m2/8 d.

76 th lovastatin, does not increase the risk of rhabdomyolysis, even when administered at a high dosage

77 Two days after rhabdomyolysis, F4/80(low)CD11b(high)Ly6b(high)CD206(low

78 The rate of myopathy and rhabdomyolysis for simvastatin 80 mg, although still low

79 ificantly higher adjusted risk of exertional rhabdomyolysis (hazard ratio, 1.54; 95% CI, 1.12 to 2.12

80 Seven months after rhabdomyolysis, histologic lesions were still present bu

81 og (Drosophila) in 12 subjects with episodic rhabdomyolysis, hypoglycemia, hyperammonemia, and suscep

82 Administration of alkali, a treatment for rhabdomyolysis, improved renal function and significantl

83 case of inflammatory polymyositis leading to rhabdomyolysis in a male patient diagnosed with Crohn's

84 Susceptibility to exertional cramps and rhabdomyolysis in myophosphorylase deficiency (McArdle's

85 The incidence of rhabdomyolysis in patients receiving 40 mg/d simvastatin

86 n implicated as the etiology of drug-induced rhabdomyolysis in several pediatric patients.

87 e-3 protein, and tubular necrosis induced by rhabdomyolysis in wild-type mice.

88 olling for known risk factors for exertional rhabdomyolysis, in a large population of active persons

89 of the LRRK2 KO rats are highly resistant to rhabdomyolysis-induced acute kidney injury compared with

90 ney injury) or by IM injections of glycerol (rhabdomyolysis-induced acute kidney injury).

91 Rhabdomyolysis-induced acute renal failure was induced i

92 was significantly lower under both basal and rhabdomyolysis-induced AKI in FtH(PT-/-) mice.

93 suggest an important role for macrophages in rhabdomyolysis-induced AKI progression and advocate the

94 abdomyolysis, but the role of macrophages in rhabdomyolysis-induced AKI remains unknown.

95 In a mouse model of rhabdomyolysis-induced AKI, diverse renal macrophage phe

96 ippel-Lindau protein (VHL-KO), protects from rhabdomyolysis-induced AKI.

97 tially protect surgical/trauma patients from rhabdomyolysis-induced ARF; and (3) further support the

98 elicited in intact rats by glycerol-induced rhabdomyolysis, induces ATP-dependent iron transport in

99 Drug-induced rhabdomyolysis is a common syndrome that is complex and

100 Rhabdomyolysis is a frequent disorder in EVD and seems t

101 Rhabdomyolysis is a potentially dangerous side effect of

102 Rhabdomyolysis is a rarer and more severe form of myopat

103 Rhabdomyolysis is defined as skeletal muscle injury that

104 statin-associated elevated liver enzymes or rhabdomyolysis is not related to the magnitude of LDL-C

105 list of drugs and inciting agents that cause rhabdomyolysis is quite extensive.

106 Progression of myalgia or myositis to rhabdomyolysis is rare (one in 30-100,000 patient-years

107 Although rhabdomyolysis is rare, muscle symptoms and serum creati

108 Severe muscle injury (rhabdomyolysis) is accompanied by the release of myoglob

109 The absolute risk increase for rhabdomyolysis may be underestimated because the codes u

110 including clinically important myositis and rhabdomyolysis, mild serum creatine kinase (CK) elevatio

111 id-lowering agents, 24 cases of hospitalized rhabdomyolysis occurred during treatment.

112 l, approximately half of the case reports of rhabdomyolysis occurred in users of this combination the

113 ower extremity paraplegia and development of rhabdomyolysis of the paraspinal muscles during the post

114 Our case describes rhabdomyolysis of the paraspinal muscles occurring after

115 rawal of cerivastatin because of deaths from rhabdomyolysis, of which 25% were related to gemfibrozil

116 tudies are needed to determine the impact of rhabdomyolysis on EVD outcome.

117 Diseases, 9th revision, diagnostic codes for rhabdomyolysis or an antihyperlipidemic adverse event, f

118 y acid oxidation defects can cause recurrent rhabdomyolysis or chronic progressive muscle weakness.

119 No episodes of rhabdomyolysis or hepatotoxicity occurred (cholesterol l

120 No cases of rhabdomyolysis or myositis occurred in either group.

121 ell tolerated, with no evidence of myopathy, rhabdomyolysis, or ophthalmologic abnormalities.

122 not of myalgias, creatine kinase elevations, rhabdomyolysis, or withdrawal of therapy compared with p

123 Incidence rates of rhabdomyolysis per 10,000 person-years of treatment, num

124 The heatstroke was complicated by seizures, rhabdomyolysis, pneumonia, renal failure, and disseminat

125 e associated with the composite end point of rhabdomyolysis, proteinuria, nephropathy, or renal failu

126 examined the composite end point of AERs of rhabdomyolysis, proteinuria, nephropathy, or renal failu

127 Reported cases of rhabdomyolysis, proteinuria, or renal failure tended to

128 vated liver enzymes (R2 <0.001, p = 0.91) or rhabdomyolysis (R2 = 0.05, p = 0.16).

129 e elevations (RD, 0.2; 95% CI, -0.6 to 0.9), rhabdomyolysis (RD, 0.4; 95% CI, -0.1 to 0.9), or discon

130 The underlying genetic etiology of rhabdomyolysis remains elusive in a significant fraction

131 System lists 3339 cases of statin-associated rhabdomyolysis reported between January 1, 1990, and Mar

132 y, which ranges in severity from myalgias to rhabdomyolysis resulting in renal failure and death.

133 Rhabdomyolysis risk was similar and low for monotherapy

134 Reliable estimates of rhabdomyolysis risk with various lipid-lowering agents a

135 aminase elevations but rates of myopathy and rhabdomyolysis similar to lower doses of statins.

136 tin was associated with much larger risks of rhabdomyolysis than other statins.

137 We previously showed in a rat model of rhabdomyolysis that redox cycling between ferric and fer

138 orts of myalgia, creatine kinase elevations, rhabdomyolysis, transaminase elevations, and discontinua

139 xicity (Amanita proxima, Amanita smithiana), rhabdomyolysis (Tricholoma equestre, Russula subnigrican

140 inadequately designed to assess the risk of rhabdomyolysis, until cerivastatin was removed from the

141 In an animal model of rhabdomyolysis, urinary excretion of F2-isoprostanes inc

142 e kinase levels were measured as a marker of rhabdomyolysis using a Vitros analyzer.

143 number needed to treat to observe 1 case of rhabdomyolysis was 22,727 for statin monotherapy, 484 fo

144 Rhabdomyolysis was diagnosed in 3 patients with HIV infe

145 th EVD than in those without (P = .002), and rhabdomyolysis was more frequent (59% vs 19%, respective

146 Here, in a patient diagnosed with rhabdomyolysis, we detected substantial macrophage infil

147 Adverse event reports of statin-associated rhabdomyolysis were also collected from the FDA MEDWATCH

148 At day 1 after rhabdomyolysis, when tubular injury may be reversible, t

149 evealed several patients with statin-induced rhabdomyolysis who also have metabolic muscle defects, i

150 Metabolic problems encountered can include rhabdomyolysis with acute renal failure.

151 eatine kinase in asymptomatic individuals to rhabdomyolysis with myoglobinuria, renal failure, and de

152 The primary outcome was hospitalization with rhabdomyolysis within 30 days of the antibiotic prescrip